[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,239,102
  • Shares Outstanding, K 84,121
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,280 K
  • EBIT $ -57 M
  • EBITDA $ -58 M
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow 108.40
  • Price/Book 5.13

Options Overview Details

View History
  • Implied Volatility 66.34% (-1.16%)
  • Historical Volatility 48.85%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 212.20% on 01/20/26
  • IV Low 66.34% on 08/12/26
  • Expected Move (DTE 9) 1.09 (7.23%)
  • Put/Call Vol Ratio 7.81
  • Today's Volume 4,663
  • Volume Avg (30-Day) 1,099
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 32,351
  • Open Int (30-Day) 33,010
  • Expected Range 13.96 to 16.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 2
  • High Estimate $-0.18
  • Low Estimate $-0.23
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.53 +20.11%
on 07/28/26
15.59 -3.43%
on 07/13/26
-0.62 (-3.96%)
since 07/10/26
3-Month
10.83 +38.97%
on 06/09/26
16.47 -8.62%
on 07/09/26
-0.92 (-5.76%)
since 05/12/26
52-Week
4.52 +232.85%
on 08/13/25
26.95 -44.16%
on 01/23/26
+10.55 (+234.44%)
since 08/12/25

Most Recent Stories

More News
Corvus: Q2 Earnings Snapshot

Corvus: Q2 Earnings Snapshot

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s potential in atopic dermatitis...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Reports Earnings as Atopic Dermatitis Trial Timeline Takes Center Stage

Barchart Research What to Expect from CRVS Earnings CRVS Generated August 5, 2026 Current Price $13.93 EPS Estimate $$-0.17 Consensus Rating Strong Buy Average Move 9.43% Corvus Pharmaceuticals Reports...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential...

CRVS : 15.05 (+2.17%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Soquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting...

CRVS : 15.05 (+2.17%)
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D.,...

CRVS : 15.05 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 15.86
2nd Resistance Point 15.58
1st Resistance Point 15.31
Last Price 15.05
1st Support Level 14.76
2nd Support Level 14.48
3rd Support Level 14.21

See More

52-Week High 26.95
Fibonacci 61.8% 18.38
Fibonacci 50% 15.74
Last Price 15.05
Fibonacci 38.2% 13.09
52-Week Low 4.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.